Tagrisso (osimertinib) receives FDA full approval
31 March 2017 07:00 BST TAGRISSO (OSIMERTINIB) RECEIVES US FDA FULL APPROVAL Conversion from accelerated to full approval confirms the potential of Tagrisso to become standard of care in the US Approval based on Phase III AURA3 trial that demonstrated significant improvement in progression-free survival with Tagrisso as compared to chemotherapy AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR)